November 8th, 2010 | 
Author: Review of prostate cancer drug Provenge renews medical cost-benefit debate
Federal officials are conducting an unusual review to determine whether the government should pay for an expensive new vaccine for treating prostate cancer, rekindling debate over whether some therapies are too costly.
Read more on Washington Post
FIX PC ERRORS
PC Integrity Scanner
Know What Happens on YOUR PC
If you enjoyed this post, make sure you subscribe to my RSS feed!
Posted in Internet Access | 
Tags: cancer, costbenefit, debate, drug, Medical, prostate, Provenge, renews, Review
